Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Riociguat

    Client Email Product

    Riociguat

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    9
    US DMFs Filed

    US DMFs Filed

    2
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    2
    Other Suppliers

    Other Suppliers

    8
    API REF. PRICE (USD / KG)
    43,235

    API Market Place

    7
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    14
    Europe

    Europe

    32
    Canada

    Canada

    5
    Australia

    Australia

    20
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    2,192.00

    Annual Reports

    731.00

    FDF Market Place

    0

    EXCIPIENTS
    129
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    25

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    2

    News

    24
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    2
    SERVICES

    0

    Full View ScreenFull Screen View
    MSN's Generic Riociguat Receives Approval in the U.S.
    MSN's Generic Riociguat Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211135

    FDA
    01 Sep 2022
    Share Share
    Bayer Announces Publication of Phase IV Adempas® (riociguat)
    Bayer Announces Publication of Phase IV Adempas® (riociguat)

    https://www.businesswire.com/news/home/20210329005176/en

    BUSINESSWIRE
    29 Mar 2021
    Share Share
    Bayer Announces Publication of Phase IV Adempas® (riociguat) Data
    Bayer Announces Publication of Phase IV Adempas® (riociguat) Data

    https://www.businesswire.com/news/home/20210329005176/en/Bayer-Announces-Publication-of-Phase-IV-Adempas%C2%AE-riociguat-Data-in-The-Lancet-Respiratory-Medicine

    BUSINESSWIRE
    29 Mar 2021
    Share Share
    Switch to Riociguat Reduces Clinical Worsening in Patients With PAH Not Meeting
    Switch to Riociguat Reduces Clinical Worsening in Patients With PAH Not Meeting

    https://www.firstwordpharma.com/node/1766758?tsid=3

    FIRSTWORDPHARMA
    20 Oct 2020
    Share Share
    Bayer Phase IV Study Met its Primary Endpoint in PAH Patients
    Bayer Phase IV Study Met its Primary Endpoint in PAH Patients

    https://www.biospace.com/article/releases/bayer-phase-iv-study-met-its-primary-endpoint-in-pah-patients-who-had-transitioned-to-adempas-riociguat-after-insufficient-response-to-pde5-inhibitors-/

    BIOSPACE
    07 Sep 2020
    Share Share
    Adempas maker Bayer launches new hypertension support group
    Adempas maker Bayer launches new hypertension support group

    https://www.fiercepharma.com/marketing/adempas-maker-bayer-connects-hypertension-patients-new-mentoring-group

    Carly Helfand FIERCE PHARMA
    14 Jul 2018
    Share Share
    Adempas®(Riociguat Tablets): Adverio Pharma Gmbh V. Teva Pharmaceuticals Usa
    Adempas®(Riociguat Tablets): Adverio Pharma Gmbh V. Teva Pharmaceuticals Usa

    https://insight.rpxcorp.com/litigation_documents/12773313

    PATENT LITIGATION
    19 Jan 2018
    Share Share
    Adempas®(Riociguat Tablets): Adverio Pharma Gmbh V. Msn Laboratories Private
    Adempas®(Riociguat Tablets): Adverio Pharma Gmbh V. Msn Laboratories Private

    https://insight.rpxcorp.com/litigation_documents/12773233

    PATENT LITIGATION
    19 Jan 2018
    Share Share
    Adempas® (Riociguat ): Adverio Pharma Gmbh V. Alembic Pharmaceuticals
    Adempas® (Riociguat ): Adverio Pharma Gmbh V. Alembic Pharmaceuticals

    https://insight.rpxcorp.com/litigation_documents/12772973

    PATENT LITIGATION
    09 Jan 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Adempas (Riociguat) Tablets
    FDA Confirms Paragraph IV Patent Challenge of Adempas (Riociguat) Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-adempas-riociguat-tablets-1512711096.pdf

    FDA
    08 Dec 2017
    Share Share
    Another record year for Bayer – good progress with the acquisition of Monsanto
    Another record year for Bayer – good progress with the acquisition of Monsanto

    http://www.press.bayer.com/baynews/baynews.nsf/id/A6E220D8E59FD1C2C12580CF001BD137

    PRESS RELEASE
    23 Feb 2017
    Share Share
    Bayer's hefty 2016 growth underlines danger of neglecting R&D for Monsanto
    Bayer's hefty 2016 growth underlines danger of neglecting R&D for Monsanto

    http://www.fiercepharma.com/pharma/bayer-s-hefty-2016-pharma-growth-underlines-danger-neglecting-r-d-for-monsanto-buy

    Tracy Staton FIERCE PHARMA
    22 Feb 2017
    Share Share
    Bayer's struggling Stivarga moves closer to liver-cancer lifeline
    Bayer's struggling Stivarga moves closer to liver-cancer lifeline

    http://www.fiercepharma.com/node/365026

    Carly Helfand FIERCE PHARMA
    04 Jan 2017
    Share Share
    Bayer’s Adempas (Riociguat) Receives Supplemental Approval in US
    Bayer’s Adempas (Riociguat) Receives Supplemental Approval in US

    https://www.pharmacompass.com/pdf/news/bayers-adempas-riociguat-receives-supplemental-approval-in-us-1475928768.pdf

    FDA
    04 Oct 2016
    Share Share
    U.S. Patent Term Extension for Bayer’s Adempas
    U.S. Patent Term Extension for Bayer’s Adempas

    http://twofourinsight.com/us-patent-term-extension-bayer-adempas/

    TWOFOUR INSIGHT
    21 Mar 2016
    Share Share
    With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio
    With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio

    http://www.fiercepharma.com/story/fda-nod-actelion-adds-blockbuster-hopeful-uptravi-pah-portfolio/2015-12-22

    Carly Helfand FIERCE PHARMA
    22 Dec 2015
    Share Share
    Actelion says selexipag to enter U.S. market in January
    Actelion says selexipag to enter U.S. market in January

    http://www.reuters.com/article/us-actelion-fda-idUSKBN0U50HO20151222

    Brenna Hughes Neghaiwi REUTERS
    22 Dec 2015
    Share Share
    GSK earns expanded approval for Volibris in Europe
    GSK earns expanded approval for Volibris in Europe

    http://www.pmlive.com/pharma_news/gsk_earns_expanded_approval_for_volibris_in_europe_874366

    Nikhil Patel PM LIVE
    26 Nov 2015
    Share Share
    Anvisa approves novel medicines for asthma, hypertension and brain tumor
    Anvisa approves novel medicines for asthma, hypertension and brain tumor

    http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+aprova+medicamentos+ineditos+para+asma%2C+hipertensao+pulmonar+e+tumor+cerebral

    ANVISA
    05 Oct 2015
    Share Share
    Gilead and GSK pulmonary hypertension drugs work in tandem
    Gilead and GSK pulmonary hypertension drugs work in tandem

    http://www.pmlive.com/pharma_news/gilead_and_gsk_pulmonary_hypertension_drugs_work_in_tandem_807320?utm_content=buffer11e7f&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

    Phil Taylor PM LIVE
    28 Aug 2015
    Share Share
    Strong start to the year for Bayer
    Strong start to the year for Bayer

    http://www.worldpharmanews.com/bayer/3078-strong-start-to-the-year-for-bayer?utm_content=buffer404ef&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

    WORLD PHARMA NEWS
    01 May 2015
    Share Share
    Bayer's Eylea Cleared for Wider Use in Europe
    Bayer's Eylea Cleared for Wider Use in Europe

    http://www.pmlive.com/pharma_news/bayers_eylea_cleared_for_wider_use_in_europe_664304

    Phil Taylor PMLIVE
    27 Feb 2015
    Share Share
    Bayer Counts On Consumer Health, Pharma Growth to Power 2015
    Bayer Counts On Consumer Health, Pharma Growth to Power 2015

    http://www.fiercepharma.com/story/bayer-counts-consumer-health-pharma-growth-power-2015/2015-02-26

    Carly Helfand FIERCE PHARMA
    26 Feb 2015
    Share Share
    Bayer HealthCare 's Adempas (Riociguat) Approved in Japan for Pulmonary Arterial Hypertension
    Bayer HealthCare 's Adempas (Riociguat) Approved in Japan for Pulmonary Arterial Hypertension

    http://www.investor.bayer.de/en/nc/news/investor-news/investor-news/adempasR-approved-in-japan-for-the-treatment-of-pulmonary-arterial-hypertension/

    Press Release BAYER
    20 Feb 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Zhejiang Riociguat

    Access Virtual Booth

    Contact Supplier

    View Presentation

    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search